Welcome to our dedicated page for Mink Therapeutics SEC filings (Ticker: INKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings rarely read like light bedtime material, and MiNK Therapeutics鈥� disclosures are no exception. Between pages of iNKT cell science, detailed R&D expense tables, and risk factors on manufacturing scale-up, investors can struggle to pinpoint what really moves the stock. That鈥檚 why our MiNK Therapeutics SEC filings page focuses on clarity first.
Stock Titan鈥檚 AI parses every 10-K annual report, 10-Q quarterly earnings report, and 8-K material event the moment MiNK submits them to EDGAR. Curious about a capital raise noted after market close? The 鈥�MiNK Therapeutics 8-K material events explained鈥� summary highlights terms in plain English. Want to monitor leadership moves? AG真人官方-time alerts surface 鈥�MiNK Therapeutics Form 4 insider transactions,鈥� letting you track executive stock purchases or sales as they post. Our engine even stitches together complex sections鈥攕o 鈥�understanding MiNK Therapeutics SEC documents with AI鈥� becomes a five-minute task, not a weekend project.
Use the page to:
- Compare R&D spend trends across each MiNK Therapeutics quarterly earnings report 10-Q filing and see cash runway projections.
- Spot patterns in 鈥�MiNK Therapeutics insider trading Form 4 transactions鈥� before key clinical milestones.
- Review the 鈥�MiNK Therapeutics proxy statement executive compensation鈥� for option grants tied to trial success.
- Dive into 鈥�MiNK Therapeutics annual report 10-K simplified鈥� sections on manufacturing scale and patent estate.
Whether you need a quick 鈥�MiNK Therapeutics earnings report filing analysis鈥� or full document downloads, our comprehensive, real-time hub lets you move from data to decisions with confidence.
MiNK Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025 and furnished a related press release as Exhibit 99.1 to this Current Report on Form 8-K. The filing states that the information under Item 2.02 and Exhibit 99.1 is being furnished and therefore is not intended to be deemed filed for purposes of Section 18 of the Exchange Act. The 8-K itself does not include the underlying financial figures; the press release referenced in Exhibit 99.1 contains the detailed results and the Cover Page Interactive Data File is included as Exhibit 104.
MiNK Therapeutics, Inc. (NASDAQ: INKT) filed a Form 8-K announcing that on 15 July 2025 it entered into an At-Market Issuance Sales Agreement with B. Riley Securities. The agreement allows the company to issue and sell up to $50 million of common stock from time to time on the open market.
The shares will be offered under the company鈥檚 effective Form S-3 shelf registration (File No. 333-268143) via a base prospectus (dated 8 Nov 2022) and a new prospectus supplement dated 15 July 2025. Sales will be made at prevailing market prices, with B. Riley acting as the agent for placement; compensation terms were not disclosed in this filing.
Exhibits include: (1) the full Sales Agreement (Ex 1.1); (2) the legal opinion and consent of Latham & Watkins LLP (Ex 5.1 & 23.1); and (3) the cover-page Inline XBRL file (Ex 104).
Key Implications for Investors
- The facility provides flexible, immediate access to capital that can support R&D, clinical trials or general corporate purposes without negotiating separate financing rounds.
- Issuances will be executed 鈥渁t-the-market,鈥� potentially creating incremental selling pressure and dilution as shares are sold into the market.
- The $50 million capacity should be evaluated relative to MiNK鈥檚 market capitalisation; if sizeable, ongoing issuance could materially increase the share count.
MiNK Therapeutics, Inc. (Nasdaq: INKT) filed an 8-K to highlight new clinical evidence supporting its allogeneic invariant natural killer T-cell therapy, agenT-797.
- Landmark peer-reviewed case: 狈补迟耻谤别鈥檚 Oncogene published a complete, durable remission (>2 years) in a patient with metastatic, treatment-refractory testicular cancer after a single agenT-797 infusion plus nivolumab (trial NCT05108623). No CRS or GVHD observed; donor iNKT cells persisted up to six months.
- Phase 2 gastric cancer signals: At the 2025 AACR Immuno-Oncology meeting, MiNK reported immune activation, increased tumor infiltration and early tumour-control signals in second-line gastric cancer patients previously refractory to checkpoint inhibitors; several patients lived >12 months post-treatment.
- Additional case report: A separate Oncogene paper detailed a metastatic gastric cancer patient who achieved a 42 % tumour reduction and >9 months progression-free survival following a single agenT-797 dose with nivolumab.
- Pipeline momentum: The ongoing Phase 2 gastric cancer study (NCT06251973) is actively enrolling, with further read-outs expected 鈥渋n upcoming months.鈥�
The filing contains forward-looking statements and reminds investors of risk factors detailed in MiNK鈥檚 March 31 2025 10-Q.
MiNK Therapeutics, Inc. (NASDAQ: INKT) filed a Form 8-K summarizing the results of its Annual Meeting of Stockholders held on 18 June 2025. A quorum was achieved with 2,793,022 shares (70.41% of outstanding) present in person or by proxy. Shareholders voted on three routine proposals outlined in the proxy dated 30 April 2025.
Proposal 1 鈥� Election of Class I Directors: Incumbents Jennifer Buell and Ulf Wiinberg were each re-elected to serve until the 2028 meeting. Support levels were strong, with Buell receiving 2,337,073 鈥淔or鈥� votes (98.7% of votes cast, excluding non-votes) and Wiinberg receiving 2,312,077 鈥淔or鈥� votes (97.7%). Broker non-votes totaled 424,803 shares.
Proposal 2 鈥� Option Exchange: Shareholders approved the company鈥檚 option exchange program, designed to allow eligible employees to exchange existing stock options for new options. The measure passed with 2,269,364 鈥淔or鈥�, 97,538 鈥淎gainst,鈥� and 1,317 鈥淎bstain,鈥� while 424,803 broker non-votes were recorded.
Proposal 3 鈥� Auditor Ratification: KPMG LLP was ratified as independent registered public accounting firm for fiscal 2025, receiving 2,773,188 鈥淔or鈥� votes (99.1%), 12,846 鈥淎gainst,鈥� and 6,988 abstentions.
No other matters were brought before the meeting, and there were no disclosures regarding financial performance, strategic transactions, or changes in control. The filing is primarily procedural, confirming continued shareholder support for existing leadership and governance practices.
FAQ
What is the current stock price of Mink Therapeutics (INKT)?
What is the market cap of Mink Therapeutics (INKT)?
